Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:43:14.355Z.
Calculation as of: 2026-10-06T21:43:14.355Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe2709ba5bee8827173e7eb2406bfc0a2a715a78b0d2155f196b4173acd92065
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$475.91M
PE Ratio
N/A
TTM Avg
16.90
3Y Avg
16.90
5Y Avg
16.90
Market Cap
$483.54M
PE Ratio
18.40
TTM Avg
12.02
3Y Avg
15.67
5Y Avg
102.65
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | $469.12M | N/A | N/A | N/A | N/A |
| Kamada Ltd. (KMDA)vs › | $467.90M | 21.40 | 21.78 | 26.84 | 31.34 |
| Cerus Corporation (CERS)vs › | $471.57M | N/A | 20.76 | 20.76 | 20.76 |
| Arvinas, Inc. (ARVN)vs › | $471.65M | 45.69 | 54.09 | 54.09 | 54.09 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.23M | N/A | N/A | N/A | N/A |
| Sight Sciences, Inc. (SGHT)vs › | $465.75M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.91M | N/A | 16.90 | 16.90 | 16.90 |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.54M | 18.40 | 12.02 | 15.67 | 102.65 |
| NRC Health (NRC)vs › | $452.54M | 79.56 | 41.70 | 28.27 | 29.07 |
| Evolus, Inc. (EOLS)vs › | $486.01M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$8.75
Forward EPS (Est.)
$-0.30
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2021-08-13 | 1035.29 |
| 2021-08-12 | 1048.13 |
| 2021-08-11 | 1063.64 |
| 2021-08-10 | 1136.36 |
| 2021-08-09 | 1134.76 |
| 2021-08-06 | 1150.27 |
| 2021-08-05 | 1139.57 |
| 2021-08-04 | 1149.73 |
| 2021-08-03 | 1146.52 |
| 2021-08-02 | 1235.29 |
| 2021-07-30 | 1188.24 |
| 2021-07-29 | 1093.05 |
| 2021-07-28 | 1024.60 |
| 2021-07-27 | 989.30 |
| 2021-07-26 | 934.22 |
| 2021-07-23 | 957.22 |
| 2021-07-22 | 958.82 |
| 2021-07-21 | 949.73 |
| 2021-07-20 | 941.71 |
| 2021-07-19 | 965.78 |
| 2021-07-16 | 1078.61 |
| 2021-07-15 | 1116.58 |
| 2021-07-14 | 1182.89 |
| 2021-07-13 | 1234.22 |
| 2021-07-12 | 1283.42 |
| 2021-07-09 | 1271.12 |
| 2021-07-08 | 1208.02 |
| 2021-07-07 | 1256.15 |
| 2021-07-06 | 1283.42 |
| 2021-07-02 | 1242.25 |
| 2021-07-01 | 1310.70 |
| 2021-06-30 | 1268.98 |
| 2021-06-29 | 1310.70 |
| 2021-06-28 | 1496.26 |
| 2021-06-25 | 1336.90 |
